[go: up one dir, main page]

DK1650303T3 - Fremgangsmåde til generering af et subtraheret cDNA-bibliotek og anvendelse af det genererede bibliotek - Google Patents

Fremgangsmåde til generering af et subtraheret cDNA-bibliotek og anvendelse af det genererede bibliotek

Info

Publication number
DK1650303T3
DK1650303T3 DK05028213T DK05028213T DK1650303T3 DK 1650303 T3 DK1650303 T3 DK 1650303T3 DK 05028213 T DK05028213 T DK 05028213T DK 05028213 T DK05028213 T DK 05028213T DK 1650303 T3 DK1650303 T3 DK 1650303T3
Authority
DK
Denmark
Prior art keywords
library
stranded
double
generating
cdna library
Prior art date
Application number
DK05028213T
Other languages
Danish (da)
English (en)
Inventor
Paul B Fisher
Hongping Jiang
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/143,576 external-priority patent/US5643761A/en
Priority claimed from US08/316,537 external-priority patent/US6051376A/en
Application filed by Univ Columbia filed Critical Univ Columbia
Application granted granted Critical
Publication of DK1650303T3 publication Critical patent/DK1650303T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1072—Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
DK05028213T 1993-10-27 1994-10-24 Fremgangsmåde til generering af et subtraheret cDNA-bibliotek og anvendelse af det genererede bibliotek DK1650303T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/143,576 US5643761A (en) 1993-10-27 1993-10-27 Method for generating a subtracted cDNA library and uses of the generated library
US08/316,537 US6051376A (en) 1994-09-30 1994-09-30 Uses of mda-6
PCT/US1994/012160 WO1995011986A1 (fr) 1993-10-27 1994-10-24 PROCEDE DE CONSTITUTION D'UNE BANQUE D'ADNc A SOUSTRACTION ET UTILISATION DE LADITE BANQUE

Publications (1)

Publication Number Publication Date
DK1650303T3 true DK1650303T3 (da) 2008-09-08

Family

ID=26841189

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05028213T DK1650303T3 (da) 1993-10-27 1994-10-24 Fremgangsmåde til generering af et subtraheret cDNA-bibliotek og anvendelse af det genererede bibliotek

Country Status (10)

Country Link
US (4) US6720408B2 (fr)
EP (3) EP0730659A4 (fr)
JP (2) JP4145953B2 (fr)
KR (1) KR100355111B1 (fr)
AT (1) ATE397066T1 (fr)
AU (1) AU695540B2 (fr)
CA (1) CA2174354C (fr)
DE (1) DE69435103D1 (fr)
DK (1) DK1650303T3 (fr)
WO (1) WO1995011986A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU692794B2 (en) * 1993-08-30 1998-06-18 Baylor College Of Medicine Senescent cell-derived inhibitors of DNA synthesis
AU695540B2 (en) 1993-10-27 1998-08-13 Trustees Of Columbia University In The City Of New York, The Method for generating a subtracted cDNA library and uses of the generated library
EP0783317B1 (fr) * 1994-05-24 2004-11-24 Baylor College Of Medicine Substances mimetiques d'inhibiteurs de la synthese de l'adn derives de cellules senescentes
US5710137A (en) * 1996-08-16 1998-01-20 The Trustees Of Columbia University In The City Of New York Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
AU5603298A (en) * 1996-12-23 1998-07-17 Schering Corporation Mammalian cytokine related to il10
US6071696A (en) * 1996-12-30 2000-06-06 The Trustees Of Columbia University In The City Of New York Method of producing a temporally spaced subtracted (TSS) CDNA library and use thereof to monitor differentiation
US6190909B1 (en) * 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
US6399334B1 (en) * 1997-09-24 2002-06-04 Invitrogen Corporation Normalized nucleic acid libraries and methods of production thereof
US6432707B1 (en) 1997-12-24 2002-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6379951B1 (en) 1997-12-24 2002-04-30 Corixa Corporation Compounds for immunotherapy of breast cancer and methods for their use
WO1999033869A2 (fr) * 1997-12-24 1999-07-08 Corixa Corporation Composes destines a l'immunotherapie et au diagnostic du cancer du sein, et leur mode d'utilisation
US6410507B1 (en) 1997-12-24 2002-06-25 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO1999037774A2 (fr) * 1998-01-26 1999-07-29 Genquest, Inc. Sequences associees a la differenciation cellulaire et procedes d'utilisation de ces sequences
WO1999037777A2 (fr) * 1998-01-26 1999-07-29 Genquest, Inc. Sequences associees a une differentiation et methodes d'utilisation
US6413717B1 (en) 1998-03-18 2002-07-02 Corixa Corporation Methods for indentifying anti-cancer agents
WO1999060124A2 (fr) * 1998-05-15 1999-11-25 Fei Huang Sequences liees a la differenciation et procede d'utilisation correspondant
US6468758B1 (en) 1998-09-23 2002-10-22 Corixa Corporation Compositions and methods for ovarian cancer therapy and diagnosis
AU2342900A (en) * 1998-09-23 2000-05-01 Cleveland Clinic Foundation, The Novel interferon stimulated and repressed genes
DE60038508T2 (de) * 1999-07-15 2009-04-30 Introgen Therapeutics Inc., Austin Methoden zur behandlung von hyperproliferativen krankheiten mit menschlichem mda-7
EP1254155A4 (fr) * 2000-01-26 2003-06-18 Univ Vanderbilt Mob-5/hmob-5 utilise comme marqueur diagnostic pour le cancer
DE10003653A1 (de) * 2000-01-28 2001-08-09 Thorsten Petrich Vektorkonstrukte zur gentherapeutisch vermittelten Radioiodtherapie entdifferenzierter und medullärer Schilddrüsen-Karzinome sowie nicht-thyreoidaler Tumore und ihrer Metastasen
US7229822B1 (en) 2000-02-29 2007-06-12 Univ Columbia Melanoma differentation associated gene-5 and vectors and cells containing same
US6841362B1 (en) 2000-02-29 2005-01-11 The Trustees Of Columbia University In The City Of New York Melanoma differentiation associated gene-7 promoter and uses thereof
WO2002045737A2 (fr) * 2000-12-07 2002-06-13 Board Of Regents, The University Of Texas System Procedes de traitement mettant en application mda-7 humain
US8008459B2 (en) 2001-01-25 2011-08-30 Evolva Sa Concatemers of differentially expressed multiple genes
DE60239386D1 (de) 2001-01-25 2011-04-21 Evolva Ltd Zellbibliothek
WO2003029262A2 (fr) 2001-08-29 2003-04-10 Vanderbilt University Recepteurs de mob-5 humains (il-24) et utilisations de ceux-ci
US7323164B2 (en) 2002-04-11 2008-01-29 Zymogenetics, Inc. Use of interleukin-24 to treat ovarian cancer
AU2003274963A1 (en) * 2002-12-23 2004-07-29 The Trustees Of Columbia University In The City Of New York Mda-7 and free radicals in the treatment of cancer
CA2548220A1 (fr) 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Utilisation de mda-7 pour inhiber des organismes infectieux pathogenes
US20080026410A1 (en) * 2004-12-02 2008-01-31 Antonia Vlahou Biomarkers for Bladder Cancer
EP1854882A4 (fr) 2005-03-01 2010-09-22 Wako Pure Chem Ind Ltd Procédé permettant d' obtenir une soustraction de polynucléotides
WO2008073615A2 (fr) * 2006-11-03 2008-06-19 The Trustees Of Columbia University In The City Of New York Mutant de n-glycosylation du gene-7 associe a la differenciation du melanome
US9476082B2 (en) 2010-05-20 2016-10-25 Evolva Sa Method of producing isoprenoid compounds in yeast
JP6667790B2 (ja) * 2014-09-19 2020-03-18 国立大学法人京都大学 Ｔ細胞リンパ腫の検査方法
WO2017078099A1 (fr) * 2015-11-06 2017-05-11 東レ株式会社 Composition pharmaceutique pour le traitement et/ou la prévention du cancer
US20190038713A1 (en) 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
KR20190112263A (ko) 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
CN112020510B (zh) 2018-03-19 2024-10-11 茂体外尔公司 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物
WO2019200013A1 (fr) 2018-04-11 2019-10-17 Cancer Targeting Systems, Inc. Combinaisons thérapeutiques pour le traitement du cancer
WO2021113644A1 (fr) 2019-12-05 2021-06-10 Multivir Inc. Combinaisons comprenant un activateur de lymphocytes t cd8+, un inhibiteur de point de contrôle immunitaire et une radiothérapie en vue d'obtenir des effets ciblés et abscopal pour le traitement du cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0212285A1 (fr) * 1985-07-29 1987-03-04 Arthur A. Gottlieb Dérivation et utilisation de produits de gènes sélectionnés
US4876187A (en) * 1985-12-05 1989-10-24 Meiogenics, Inc. Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences
AU1626288A (en) * 1987-04-02 1988-11-02 Genelabs Incorporated Equal-abundance transcript composition and method
DE3722958A1 (de) * 1987-07-11 1989-01-19 Heinrich Dr Klefenz Verfahren zur identifizierung und/oder isolierung spezifischer molekuele bzw. molekuelpopulationen
US6107023A (en) * 1988-06-17 2000-08-22 Genelabs Technologies, Inc. DNA amplification and subtraction techniques
AU628451B2 (en) * 1988-12-07 1992-09-17 General Hospital Corporation, The Method of enrichment and cloning for dna containing an insertion or corresponding to a deletion
JPH05508305A (ja) * 1989-10-16 1993-11-25 ジエネラブス・テクノロジーズ・インコーポレイテツド 非特異的ｄｎａ増幅
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
AU695540B2 (en) * 1993-10-27 1998-08-13 Trustees Of Columbia University In The City Of New York, The Method for generating a subtracted cDNA library and uses of the generated library
US5643761A (en) 1993-10-27 1997-07-01 The Trustees Of Columbia University In The City Of New York Method for generating a subtracted cDNA library and uses of the generated library
US6051376A (en) 1994-09-30 2000-04-18 The Trustees Of Columbia University In The City Of New York Uses of mda-6
US5710137A (en) 1996-08-16 1998-01-20 The Trustees Of Columbia University In The City Of New York Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
AU5603298A (en) 1996-12-23 1998-07-17 Schering Corporation Mammalian cytokine related to il10
US6190909B1 (en) 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
US6413717B1 (en) 1998-03-18 2002-07-02 Corixa Corporation Methods for indentifying anti-cancer agents
DE60038508T2 (de) 1999-07-15 2009-04-30 Introgen Therapeutics Inc., Austin Methoden zur behandlung von hyperproliferativen krankheiten mit menschlichem mda-7
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US20030082140A1 (en) * 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
US20080026410A1 (en) * 2004-12-02 2008-01-31 Antonia Vlahou Biomarkers for Bladder Cancer

Also Published As

Publication number Publication date
US20030225025A1 (en) 2003-12-04
AU8088394A (en) 1995-05-22
CA2174354A1 (fr) 1995-05-04
EP1650303A3 (fr) 2006-05-10
EP1329509A3 (fr) 2003-10-15
EP0730659A1 (fr) 1996-09-11
US20020183509A1 (en) 2002-12-05
JP4205136B2 (ja) 2009-01-07
JP4145953B2 (ja) 2008-09-03
CA2174354C (fr) 2011-03-29
KR100355111B1 (ko) 2003-03-03
US20110136224A1 (en) 2011-06-09
WO1995011986A1 (fr) 1995-05-04
EP1650303B1 (fr) 2008-05-28
EP0730659A4 (fr) 1999-03-31
EP1650303A2 (fr) 2006-04-26
US6720408B2 (en) 2004-04-13
US20090246272A1 (en) 2009-10-01
DE69435103D1 (de) 2008-07-10
EP1329509A2 (fr) 2003-07-23
JPH09507021A (ja) 1997-07-15
JP2007300928A (ja) 2007-11-22
AU695540B2 (en) 1998-08-13
KR960706565A (ko) 1996-12-09
US7507792B2 (en) 2009-03-24
ATE397066T1 (de) 2008-06-15

Similar Documents

Publication Publication Date Title
DK1650303T3 (da) Fremgangsmåde til generering af et subtraheret cDNA-bibliotek og anvendelse af det genererede bibliotek
EP1961826A3 (fr) Procédé de séquençage direct d'acides nucléiques
ATE239090T1 (de) Methode zum generieren von einzelsträngigen dna molekülen
WO1999014375A3 (fr) Recherche de type de genes par spectrometrie de masse avec marqueurs de sequences repetees d'adn polymorphes
PL325439A1 (en) Oligonucleotides, method of amplifying nuclein acid and set of means for acrrying out such amplification of nucleic acid
DE69837913D1 (de) Verfahren zur vervielfältigung von nukleinsäure
WO2000040755A3 (fr) Acceleration de l'identification des polymorphismes d'un nucleotide unique et alignement de clones dans le sequençage genomique
DK1423528T3 (da) Fremgangsmåde til bestemmelse af methyleringsgraden af bestemte cytosiner i genomisk DNA i sekvenskonteksten 5-CPG-3
DK144886D0 (da) Fremgangsmaade til multiplikation af en specifik nukleinsyresekvens
CA2421767A1 (fr) Procede et trousse permettant de determiner l'origine geographique ou demographique d'un etre humain
DK0912767T3 (da) Fremgangsmåde til sporing og forstærkning af nukleinsyresekvenser ved anvendelse af modificerede oligonukleotider med foröget targetspecifikt TM
DE60115811D1 (de) Amplifizierung unter Verwendung von modifizierten Primern
ES2174063T3 (es) Procedimiento para la amplificacion de secuencias especificas de acidonucleico.
ATE267879T1 (de) Polymerasesignalversuch
EP1212449A4 (fr) Amplification de sequences flanquantes a partir d'adn inconnu
ATE361377T1 (de) Leistungstarke verknüpfung von nukleinsäuresegmenten
DK0707659T3 (da) Identifikation af Salmonella ved hjælp af polymerasekædereaktion
AR017917A1 (es) Metodo para seleccionar una primer planta por seleccion asistida por marcadores de un polimorfismo nucleotido, metodo para detectar un polimorfismonucleotidico genetico en una muestra biologica de una planta de soja, metodo de separacion de dos acidos nucleicos, metodo de amplificar un acido nucleic
WO2001029262A3 (fr) Reactifs de genotypage, kits et procedes d'utilisation desdits reactifs
WO2000000638A3 (fr) Marquage d'amplicons d'arn produits au moyen d'une amplification fondee sur la transcription
WO1995017522A3 (fr) Identification de sequences repetees simples en tandem
BR0316224A (pt) Sequência de dna da região genÈmica tcd de photorhabdus luminescens
WO2002059348A3 (fr) Procede de determination de l'affinite genetique de micro-organismes et de virus
EP1411117A4 (fr) Oligonucleotides utilises dans la detection du bacille de la tuberculose et procede correspondant
US7264931B2 (en) Method for sequencing nucleic acid sequences without chain termination